Patents by Inventor Steven Oberste
Steven Oberste has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10137188Abstract: Provided herein are engineered cell lines. In some embodiments, cells of an engineered cell line have altered expression of a gene and/or altered expression of an miRNA, wherein the altered expression results in increased or decreased production of a virus. The virus is a picornavirus, such as a poliovirus or Enterovirus 71. Also provided herein are methods for using the engineered cells to produce virus, and methods for treating a subject having or at risk of having a viral infection.Type: GrantFiled: February 5, 2014Date of Patent: November 27, 2018Assignees: University of Georgia Research Foundation, Inc., The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Thermo Fisher Scientific, Inc.Inventors: Jon Michael Karpilow, Mark Steven Oberste, Ralph A. Tripp, Stephen M. Tompkins
-
Patent number: 9938588Abstract: Methods and compositions for detection of enterovirus D in a sample, particularly detection of enterovirus D68, are provided. The methods include contacting a sample with at least one primer (such as a forward primer and/or a reverse primer) capable of specifically amplifying an EV-D68 viral protein 1 (VP1) nucleic acid or a portion thereof and/or a detectably labeled probe capable of specifically hybridizing to an EV-D68 VP1 nucleic acid, under conditions sufficient for specific amplification of the EV-D68 VP1 nucleic acid by the at least one primer and/or under conditions sufficient for specific hybridization of the probe to the EV-D68 nucleic acid. The amplification of the EV-D68 VP1 nucleic acid and/or the hybridization of the probe to the EV-D68 VP1 nucleic acid is detected, thereby identifying presence of EV-D68 in the sample.Type: GrantFiled: June 3, 2016Date of Patent: April 10, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: William Allan Nix, M. Steven Oberste
-
Publication number: 20170151322Abstract: Provided herein are engineered cell lines. In some embodiments, cells of an engineered cell line have altered expression of a gene and/or altered expression of an miRNA, wherein the altered expression results in increased or decreased production of a virus. The virus is a picomavirus, such as a poliovirus or Enterovirus 71. Also provided herein are methods for using the engineered cells to produce virus, and methods for treating a subject having or at risk of having a viral infection.Type: ApplicationFiled: February 5, 2014Publication date: June 1, 2017Inventors: Jon Michael Karpilow, Mark Steven Oberste, Ralph A. Tripp, Stephen M. Tompkins
-
Publication number: 20160355897Abstract: Disclosed herein are methods and compositions for detection of enterovirus D in a sample, particularly detection of enterovirus D68. The methods include contacting a sample with at least one primer (such as a forward primer and/or a reverse primer) capable of specifically amplifying an EV-D68 viral protein 1 (VP1) nucleic acid or a portion thereof and/or a detectably labeled probe capable of specifically hybridizing to an EV-D68 VP1 nucleic acid, under conditions sufficient for specific amplification of the EV-D68 VP1 nucleic acid by the at least one primer and/or under conditions sufficient for specific hybridization of the probe to the EV-D68 nucleic acid. The amplification of the EV-D68 VP1 nucleic acid and/or the hybridization of the probe to the EV-D68 VP1 nucleic acid is detected, thereby identifying presence of EV-D68 in the sample.Type: ApplicationFiled: June 3, 2016Publication date: December 8, 2016Inventors: William Allan Nix, M. Steven Oberste
-
Publication number: 20150374812Abstract: Provided herein are engineered cell lines. In some embodiments, cells of an engineered cell line have altered expression of a gene and/or altered expression of an miRNA, wherein the altered expression results in increased or decreased production of a virus. The virus is a picomavirus, such as a poliovirus or Enterovirus 71. Also provided herein are methods for using the engineered cells to produce virus, and methods for treating a subject having or at risk of having a viral infection.Type: ApplicationFiled: February 5, 2014Publication date: December 31, 2015Inventors: Jon Michael Karpilow, Mark Steven Oberste, Ralph A. Tripp, Stephen M. Tompkins
-
Patent number: 8048630Abstract: The present disclosure provides methods that permit detection of all known species of Parechovirus, including Human parechovirus and Ljungan virus (LV). In particular examples the method includes amplifying at least a portion of the 5?NTR of parechovirus nucleic acid molecules obtained from a sample, and detecting the resulting amplicons, but does not require culturing of the virus. The present disclosure also provides methods for determining which particular species or serotype of parechovirus is present in a biological sample. Also provided are oligonucleotide primers and probes that can be used in the disclosed methods.Type: GrantFiled: May 1, 2006Date of Patent: November 1, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: William Allan Nix, M. Steven Oberste
-
Patent number: 7776521Abstract: Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.Type: GrantFiled: May 14, 2007Date of Patent: August 17, 2010Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Paul A. Rota, Larry J. Anderson, William J. Bellini, Michael D. Bowen, Cara Carthel Burns, Raymond Campagnoli, Qi Chen, James A. Comer, Byron T. Cook, Shannon L. Emery, Dean D. Erdman, Cynthia S. Goldsmith, Jeanette Guarner, Charles D. Humphrey, Joseph P. Icenogle, Thomas G. Ksiazek, Richard F. Meyer, Stephan S. Monroe, William Allan Nix, M. Steven Oberste, Christopher D. Paddock, Teresa C. T. Peret, Pierre E. Rollin, Mark A. Pallansch, Anthony Sanchez, Wun-Ju Shieh, Suxiang Tong, Sherif R. Zaki
-
Patent number: 7714122Abstract: Disclosed are methods of using enterovirus-specific primers for the detection and identification of enterovirus infection. Also provided are isolated nucleic acid molecules and kits useful for detection and diagnostic testing of enterovirus infection in a subject.Type: GrantFiled: July 13, 2007Date of Patent: May 11, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: William Allan Nix, M. Steven Oberste
-
Publication number: 20100035230Abstract: The present disclosure provides methods that permit detection of all known species of Parechovirus, including Human parechovirus and Ljungan virus (LV). In particular examples the method includes amplifying at least a portion of the 5?NTR of parechovirus nucleic acid molecules obtained from a sample, and detecting the resulting amplicons, but does not require culturing of the virus. The present disclosure also provides methods for determining which particular species or serotype of parechovirus is present in a biological sample. Also provided are oligonucleotide primers and probes that can be used in the disclosed methods.Type: ApplicationFiled: May 1, 2006Publication date: February 11, 2010Inventors: William Allan Nix, M. Steven Oberste
-
Patent number: 7435539Abstract: The present invention discloses a method for detecting the presence of an enterovirus in a clinical sample. The invention additionally discloses a method for typing an enterovirus in a clinical sample. Both methods employ a set of primer oligonucleotides for reverse transcription and amplification that hybridize to conserved regions of the enterovirus genome, and that provide amplicons that include significant portions of the VP1 region that are characteristic of the various serotypes. In the typing method, the invention further provides a database consisting of nucleotide sequences from prototypical enteroviral serotypes, which is used to type the clinical sample by comparing the sequence of its amplicon with each prototypical sequence in the database. The invention additionally provides mixtures of primer oligonucleotides, and a kit for use in conducting the typing method that includes a mixture of the primer oligonucleotides.Type: GrantFiled: January 25, 2005Date of Patent: October 14, 2008Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Steven Oberste, Kaija Maher, David R. Kilpatrick, Mark A. Pallansch
-
Patent number: 7247457Abstract: Disclosed are methods of using enterovirus-specific primers for the detection and identification of enterovirus infection. Also provided are isolated nucleic acid molecules and kits useful for detection and diagnostic testing of enterovirus infection in a subject.Type: GrantFiled: April 26, 2005Date of Patent: July 24, 2007Assignee: United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: William Allan Nix, M. Steven Oberste
-
Patent number: 7220852Abstract: Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.Type: GrantFiled: April 12, 2004Date of Patent: May 22, 2007Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Paul A. Rota, Larry J. Anderson, William J. Bellini, Cara Carthel Burns, Raymond Campagnoli, Qi Chen, James A. Comer, Shannon L. Emery, Dean D. Erdman, Cynthia S. Goldsmith, Charles D. Humphrey, Joseph P. Icenogle, Thomas G. Ksiazek, Stephan S. Monroe, William Allan Nix, M. Steven Oberste, Teresa C. T. Peret, Pierre E. Rollin, Mark A. Pallansch, Anthony Sanchez, Suxiang Tong, Sherif R. Zaki
-
Publication number: 20050123908Abstract: The present invention discloses a method for detecting the presence of an enterovirus in a clinical sample. The invention additionally discloses a method for typing an enterovirus in a clinical sample. Both methods employ a set of primer oligonucleotides for reverse transcription and amplification that hybridize to conserved regions of the enterovirus genome, and that provide amplicons that include significant portions of the VP1 region that are characteristic of the various serotypes. In the typing method, the invention further provides a database consisting of nucleotide sequences from prototypical enteroviral serotypes, which is used to type the clinical sample by comparing the sequence of its amplicon with each prototypical sequence in the database.Type: ApplicationFiled: January 25, 2005Publication date: June 9, 2005Inventors: Steven Oberste, Kaija Maher, David Kilpatrick, Mark Pallansch
-
Patent number: 6846621Abstract: The present invention discloses a method for detecting the presence of an enterovirus in a clinical sample. The invention additionally discloses a method for typing an enterovirus in a clinical sample. Both methods employ a set of primer oligonucleotides for reverse transcription and amplification that hybridize to conserved regions of the enterovirus genome, and that provide amplicons that include significant portions of the VP1 region that are characteristic of the various serotypes. In the typing method, the invention further provides a database consisting of nucleotide sequences from prototypical enteroviral serotypes, which is used to type the clinical sample by comparing the sequence of its amplicon with each prototypical sequence in the database. The invention additionally provides mixtures of primer oligonucleotides, and a kit for use in conducting the typing method that includes a mixture of the primer oligonucleotides.Type: GrantFiled: March 24, 2000Date of Patent: January 25, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Steven Oberste, Kaija Maher, David R. Kilpatrick, Mark A. Pallansch
-
Patent number: 6261570Abstract: cDNAs coding for an infectious Western Equine Encephalitis virus (WEE) and infectious Venezuelan Equine Encephalitis virus variant IE (VEE IE) are disclosed in addition to cDNA coding for the structural proteins of Venezuelan Equine Encephalitis virus variant IIIA (VEE IIIA). Novel attenuating mutations of WEE and VEE IE and their uses are described. Also disclosed are attenuated chimearic alphaviruses and their uses.Type: GrantFiled: December 16, 1997Date of Patent: July 17, 2001Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Michael D. Parker, Jonathan F. Smith, Bruce J. Crise, Mark Steven Oberste, Shannon M. Schmura